On May 16, 2019 Incyte Corporation (Nasdaq:INCY) reported that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24thCongress of the European Hematology Association (EHA) (Free EHA Whitepaper), to be held June 13-16, 2019, in Amsterdam, the Netherlands (Press release, Incyte, MAY 16, 2019, View Source [SID1234536416]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstracts accepted for presentation at ASCO (Free ASCO Whitepaper) feature genomic profiling data from Incyte’s ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY mono-1 trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA (Free EHA Whitepaper) will showcase the continued study of Incyte’s JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms (MPNs).
"Our presence at ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) illustrates Incyte’s ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are pleased to highlight new data on two investigational medicines – pemigatinib and capmatinib – that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs."
Key ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) abstracts include:
ASCO Abstracts
Oral Presentation
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study (Abstract #9004, oral abstract session)
Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1
Poster Presentation
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma (Abstract #4080, poster session)
Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A
EHA Abstracts
Poster Presentations
Impact of myeloproliferative neoplasms (MPNS) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey(Abstract #PF681, poster presentation)
Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Real-world safety data from a non-interventional long-term post authorization safety study of ruxolitinib in myelofibrosis (Abstract #PF679, poster presentation)
Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (hemoglobin <10g/dL):Results at Week 24 of the REALISE trial (Abstract #PS1465, poster presentation)
Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area
For full session details and data presentation listings, please see the ASCO (Free ASCO Whitepaper) (View Source) and EHA (Free EHA Whitepaper) (View Source) online programs.
Where the use of compounds described herein is either investigational or being studied for (a) new use(s), efficacy and safety have not been established, and there is no guarantee that such compounds will become commercially available for the use(s) under investigation.